[
  {
    "ts": null,
    "headline": "Dow Loses About 350 Points After Record-Breaking Run",
    "summary": "A slide in shares of pharmaceutical firm  Merck  and biotech company  Amgen  helped drag the blue-chip index back from the highs notched in the broad rally Friday after Federal Reserve Chair  Jerome Powell  signaled that the central bank could lower interest rates next month.  The Dow fell 0.8%, with Merck losing 2.4% and Amgen falling 1.8%.  “There is some lack of comfort that Powell’s assertion that tariffs will be mostly a one-time increase in prices will be how things actually play out,” wrote  Louis Navellier,  chief investment officer of Navellier & Associates, in a Monday note.",
    "url": "https://finnhub.io/api/news?id=ef73ff0b2f68a5d9975a5b189d83cbeebe7b147173e27cb8e4a366e9a666040f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756154220,
      "headline": "Dow Loses About 350 Points After Record-Breaking Run",
      "id": 136523948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A slide in shares of pharmaceutical firm  Merck  and biotech company  Amgen  helped drag the blue-chip index back from the highs notched in the broad rally Friday after Federal Reserve Chair  Jerome Powell  signaled that the central bank could lower interest rates next month.  The Dow fell 0.8%, with Merck losing 2.4% and Amgen falling 1.8%.  “There is some lack of comfort that Powell’s assertion that tariffs will be mostly a one-time increase in prices will be how things actually play out,” wrote  Louis Navellier,  chief investment officer of Navellier & Associates, in a Monday note.",
      "url": "https://finnhub.io/api/news?id=ef73ff0b2f68a5d9975a5b189d83cbeebe7b147173e27cb8e4a366e9a666040f"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Drops, Apple Firm Despite Musk Threat; Cathie Wood Loads Up On This Stock (Live Coverage)",
    "summary": "The Dow fell as Nvidia shined on the stock market today. Apple held up despite an Elon Musk AI move. Cathie Wood bought a diving stock.",
    "url": "https://finnhub.io/api/news?id=741cc617526e6af9d4f9f3bc5a38ad75e609a0e15933233540034f15031a65bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756153867,
      "headline": "Stock Market Today: Dow Drops, Apple Firm Despite Musk Threat; Cathie Wood Loads Up On This Stock (Live Coverage)",
      "id": 136522222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Dow fell as Nvidia shined on the stock market today. Apple held up despite an Elon Musk AI move. Cathie Wood bought a diving stock.",
      "url": "https://finnhub.io/api/news?id=741cc617526e6af9d4f9f3bc5a38ad75e609a0e15933233540034f15031a65bc"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Unveils New Cardiovascular Research Data at ESC 2025 Congress",
    "summary": "Merck (MRK) is set to present new clinical trial data at the European Society of Cardiology Congress 2025, emphasizing advancements in cardiovascular disease management. Over the last quarter, Merck's stock price increased by 13%, aligning closely with the overall market upswing driven by investor optimism regarding interest rate cuts. While Merck's developments, such as the clinical and regulatory progress with its drugs like WINREVAIR and KEYTRUDA, added weight to the company's movements,...",
    "url": "https://finnhub.io/api/news?id=f374b14a2b8ec2f135321e106e105b872fdf7c117032d48e025a90e9ec25e342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756142728,
      "headline": "Merck (MRK) Unveils New Cardiovascular Research Data at ESC 2025 Congress",
      "id": 136522460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) is set to present new clinical trial data at the European Society of Cardiology Congress 2025, emphasizing advancements in cardiovascular disease management. Over the last quarter, Merck's stock price increased by 13%, aligning closely with the overall market upswing driven by investor optimism regarding interest rate cuts. While Merck's developments, such as the clinical and regulatory progress with its drugs like WINREVAIR and KEYTRUDA, added weight to the company's movements,...",
      "url": "https://finnhub.io/api/news?id=f374b14a2b8ec2f135321e106e105b872fdf7c117032d48e025a90e9ec25e342"
    }
  },
  {
    "ts": null,
    "headline": "Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?",
    "summary": "EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.",
    "url": "https://finnhub.io/api/news?id=e8ce0022f30d9ac7b595512ce752c1f427d1661cf8208bc5e9669d02ba1263b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756125900,
      "headline": "Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?",
      "id": 136508036,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.",
      "url": "https://finnhub.io/api/news?id=e8ce0022f30d9ac7b595512ce752c1f427d1661cf8208bc5e9669d02ba1263b4"
    }
  },
  {
    "ts": null,
    "headline": "HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market",
    "summary": "Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern University on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on disco",
    "url": "https://finnhub.io/api/news?id=553430f804e4f301bb24c7e6efa4d9a599175515f34871604c68d865d271ad16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756123200,
      "headline": "HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market",
      "id": 136508037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern University on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on disco",
      "url": "https://finnhub.io/api/news?id=553430f804e4f301bb24c7e6efa4d9a599175515f34871604c68d865d271ad16"
    }
  },
  {
    "ts": null,
    "headline": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
    "summary": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
    "url": "https://finnhub.io/api/news?id=7aa241ab7c2ce1d8ae7bfc08d74b41adebb2a4bbe3b469035f1aa4153ab3640c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756122360,
      "headline": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
      "id": 136528035,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
      "url": "https://finnhub.io/api/news?id=7aa241ab7c2ce1d8ae7bfc08d74b41adebb2a4bbe3b469035f1aa4153ab3640c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025",
    "summary": "RAHWAY, N.J., August 25, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain from August 29 – September 1. Data presented at ESC include Merck’s latest research focusing on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF).",
    "url": "https://finnhub.io/api/news?id=b04504ca9773f938b7c894b11c23fd8bc6b4d8f97a7e4a0985512acececbc6d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756118700,
      "headline": "Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025",
      "id": 136508039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., August 25, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain from August 29 – September 1. Data presented at ESC include Merck’s latest research focusing on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF).",
      "url": "https://finnhub.io/api/news?id=b04504ca9773f938b7c894b11c23fd8bc6b4d8f97a7e4a0985512acececbc6d5"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK): Valuation Update Following FDA Breakthrough in Oncology and New Approvals",
    "summary": "Merck (MRK) is seeing renewed attention from investors this week, thanks to a pivotal event in its oncology pipeline. The company, in collaboration with Daiichi Sankyo, just secured Breakthrough Therapy Designation from the U.S. FDA for ifinatamab deruxtecan. This therapy is aimed at treating extensive-stage small cell lung cancer after chemotherapy. For those considering their options with the stock, this regulatory win highlights that Merck’s investment in innovative therapies could bring...",
    "url": "https://finnhub.io/api/news?id=22ad4909a11362e054e35fa8039fc01f86c3d1913cc6b57b2bb1b9e4bee6172c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756116617,
      "headline": "Merck (MRK): Valuation Update Following FDA Breakthrough in Oncology and New Approvals",
      "id": 136508040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) is seeing renewed attention from investors this week, thanks to a pivotal event in its oncology pipeline. The company, in collaboration with Daiichi Sankyo, just secured Breakthrough Therapy Designation from the U.S. FDA for ifinatamab deruxtecan. This therapy is aimed at treating extensive-stage small cell lung cancer after chemotherapy. For those considering their options with the stock, this regulatory win highlights that Merck’s investment in innovative therapies could bring...",
      "url": "https://finnhub.io/api/news?id=22ad4909a11362e054e35fa8039fc01f86c3d1913cc6b57b2bb1b9e4bee6172c"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Sherwin-Williams Co. share losses lead Dow's 125-point drop",
    "summary": "Merck, Sherwin-Williams Co. share losses lead Dow's 125-point drop",
    "url": "https://finnhub.io/api/news?id=80f1cf80290a4d8c0528d2e89c2779bd31c6c034e99ad454c6d5742984d53479",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756115280,
      "headline": "Merck, Sherwin-Williams Co. share losses lead Dow's 125-point drop",
      "id": 136527955,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck, Sherwin-Williams Co. share losses lead Dow's 125-point drop",
      "url": "https://finnhub.io/api/news?id=80f1cf80290a4d8c0528d2e89c2779bd31c6c034e99ad454c6d5742984d53479"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: Why I Decided To Invest In The Stock",
    "summary": "Zoetis: Why I Decided To Invest In The Stock",
    "url": "https://finnhub.io/api/news?id=5ef5bfa317082084be99504402bde890939487b3c835c9cec259c0e9eba64002",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756086309,
      "headline": "Zoetis: Why I Decided To Invest In The Stock",
      "id": 136506141,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5ef5bfa317082084be99504402bde890939487b3c835c9cec259c0e9eba64002"
    }
  },
  {
    "ts": null,
    "headline": "Harbour BioMed Appoints Yajie Li as Chief Medical Officer",
    "summary": "Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.",
    "url": "https://finnhub.io/api/news?id=e59b4ca631e8e6e1772f34c92c47b578300a9b4a39781df7faf17ee2a02ded8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756083600,
      "headline": "Harbour BioMed Appoints Yajie Li as Chief Medical Officer",
      "id": 136507920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.",
      "url": "https://finnhub.io/api/news?id=e59b4ca631e8e6e1772f34c92c47b578300a9b4a39781df7faf17ee2a02ded8b"
    }
  }
]